Navigation Links
DIA Conference to Focus on Clinical Trial Disclosure and the Importance of Transparency
Date:9/10/2013

HORSHAM, Pa (PRWEB) September 10, 2013

The DIA conference Clinical Trial Disclosure: Towards a More Transparent World will provide guidance on potential implications of the transparency of clinical trial information in registration, reporting and more. The meeting, to be held Oct. 1 to 2 in Bethesda, Md., will bring together academics, government regulators and patient advocates to provide key guidance on:

  •     Requirements for clinical trial disclosure in the United States and the European Union
  •     The interaction among medical writing, regulatory affairs and clinical trial disclosure to maintain consistency for protocol registration and the reporting of results
  •     The impact of greater transparency in clinical trial disclosure on industry and academia
  •     The advantages and implications of the availability of clinical trial disclosure databases

“The continuing proliferation of national and industry-sponsored registries leaves many sponsors considering disclosure strategy, developing operational measures and looking for efficient ways to manage dissemination of clinical trial protocol information. We are excited to bring together these leaders to discuss moving the needle in clinical trial disclosures,” said Susan Cantrell, director of DIA North America.

Speakers include:

  •     Jarilyn Dupont, director of regulatory policy, Food and Drug Administration
  •     Mark Barnes, partner, Ropes & Gray LLP
  •     Chris Galvin, analyst, Office of Inspector General, U.S. Department of Health and Human Services
  •     Jessica B. Gilbart, president and CEO, DC/MD/VA Chapter, Lupus Foundation of America
  •     Christine Laine, M.D., editor, Annals of Internal Medicine, and senior vice president, American College of Physicians
  •     Joseph Solomon Ross, M.D., assistant professor of medicine (general medicine) and of public health (health policy), Yale School of Medicine
  •     Michael Krumenacker, M.D., publication compliance officer, Sanofi

To find out more about the event and to register, visit DIA’s website for Clinical Trial Disclosure: Towards a More Transparent World.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at http://www.diahome.org and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.

###

Read the full story at http://www.prweb.com/releases/2013/9/prweb11109637.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Elsevier organizes label-free technologies conference
2. NJ stroke researchers report advances in spatial neglect research at AAN Conference
3. Blending conference translates substance abuse research into practice
4. International conference to explore health of descendants of transatlantic slave trade
5. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
6. Nobel laureate to keynote international pharmaceutical conference at URI
7. Pharmica Consulting to Hold HIT Conference for the Pharmaceutical Industry
8. Snoring Isn't Sexy Member Dr. Mark Levy attends Academy of Clinical Sleep Disorders Disciplines Conference in Phoenix, Arizona
9. AuntMinnie Begins Live Video Stream of ISCT Conference Proceedings
10. NOVAtime Solutions to be showcased at Booth #1821 in the upcoming Society for Human Resource Management (SHRM) Annual Conference and Exposition
11. International Nanomedicine Conference bound for Sydney: July 2-4, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... New Jersey (PRWEB) , ... February 27, 2017 , ... ... highest cancer rates, among all types and genders. And the need for advanced services ... by RWJ and its top-rated cancer care program, in collaboration with their non-profit partners ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards ... of International Social Design Awards. , The 7th A' Social Design Award ... and Institutions worldwide with realized projects and conceptual works. , The first phase ...
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... ... ... IndustryArchive.Org . is announcing a new way for B2B Sellers to ... pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase a ... that B2B buyers are controlling the sales process via the Internet and that ad ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  International Biophysics Corporation, a ... , today announced a 34% revenue growth in 2016 ... increase in unit sales.  This growth was fueled by its ... in addition to the expansion of its global sales of ... International Biophysics, CEO, "As we enter our 25 th ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
(Date:2/27/2017)... 27, 2017 Leading Countries, Technologies and Companies ... expected to grow at a CAGR of 8.9% from 2016-2021 and ... at a CAGR of 9.1% from 2016 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
Breaking Medicine Technology: